Recombinant Antigen for Newcastle Disease Virus Vaccine Focusing on Currently Circulating Virus Variants.
- 1Department of Virology, Faculty of Biology, Lomonosov Moscow State University, 119234 Moscow, Russia.
- 2Chumakov Federal Scientific Center for Research and Development of Immune and Biological Products, Russian Academy of Sciences, 108819 Moscow, Russia.
- 3All-Russian Scientific Research and Technological Institute of Biological Industry, 17, Biocombinat, 141142 Moscow, Russia.
Abstract
Newcastle disease virus (NDV) causes a highly contagious avian infection and is characterised by its high genetic diversity and mutation rate. Currently applied vaccines are based on NDV genotypes I and II, which are considerably distinct from the circulating pathogenic genotypes, of which genotype VII is predominant, and therefore, they may not provide complete protection for birds or stop virus transmission. This work is a proof-of-concept study aiming to develop a genotype VII-focused recombinant antigen for a vaccine targeting relevant NDV strains. The research primarily focuses on novel antigen design based on the bioinformatics analysis of recent circulating isolates. Haemagglutinin-neuraminidase (HN) is one of the two main NDV antigens. Two HN fragments ("1"-341-368 aa and "2"-239-257 aa) were selected due to the presence of linear neutralising epitopes. An approach focusing on using a number of selected-fragment variants simultaneously was applied for the first time. The resulting antigen Castle1 encompasses the sequence diversity of most circulating isolates. Preliminary immunological evaluation showed that antibodies from Castle1-immunised animals possessed haemagglutination inhibition activity and interacted with NDV of genotypes I and VII. That makes Castle1 a promising antigen for the further development of a vaccine for preventing ongoing and incoming NDV outbreaks.
Related
- Combined Vaccination with Recombinant HVT-ND and Live Newcastle Disease Vaccines Accelerates Early Immunity, Limits Virus Shedding and Reduces Transmission.
- A screening assay for type 2B von Willebrand factor variants using an enzyme-linked immunosorbent assay based on recombinant wild-type glycoprotein Ib and ristocetin.
- Prevalence of NASH/NAFLD in people with obesity who are currently classified as metabolically healthy
- Determinants of comprehensive knowledge of mother-to-child transmission of HIV among currently married women in Somalia: analysis of the 2020 Somali Demographic and Health Survey
- Predictors of e-cigarette discontinuation among a US national cross-sectional sample of adults who currently smoke.
BibTeX
@article{umarova2026recombinant,
title = {{Recombinant Antigen for Newcastle Disease Virus Vaccine Focusing on Currently Circulating Virus Variants.}},
author = {Elizaveta P Umarova and Ekaterina M Ryabchevskaya and Dmitriy L Granovskiy and Ekaterina A Evtushenko and Angelina O Kovalenko and Elizaveta Yu Boravleva and Alexandra S Gambaryan and Irina N Matveeva and Nikolai A Nikitin and Olga V Karpova},
journal = {International journal of molecular sciences},
year = {2026},
month = sep,
doi = {10.3390/ijms27198673},
url = {https://europepmc.org/article/MED/42883918},
note = {CC BY},
}
RIS
TY - JOUR
TI - Recombinant Antigen for Newcastle Disease Virus Vaccine Focusing on Currently Circulating Virus Variants.
AU - Elizaveta P Umarova
AU - Ekaterina M Ryabchevskaya
AU - Dmitriy L Granovskiy
AU - Ekaterina A Evtushenko
AU - Angelina O Kovalenko
AU - Elizaveta Yu Boravleva
AU - Alexandra S Gambaryan
AU - Irina N Matveeva
AU - Nikolai A Nikitin
AU - Olga V Karpova
PY - 2026
DA - 2026/09/28
JO - International journal of molecular sciences
DO - 10.3390/ijms27198673
UR - https://europepmc.org/article/MED/42883918
AB - Newcastle disease virus (NDV) causes a highly contagious avian infection and is characterised by its high genetic diversity and mutation rate. Currently applied vaccines are based on NDV genotypes I and II, which are considerably distinct from the circulating pathogenic genotypes, of which genotype VII is predominant, and therefore, they may not provide complete protection for birds or stop virus transmission. This work is a proof-of-concept study aiming to develop a genotype VII-focused recombinant antigen for a vaccine targeting relevant NDV strains. The research primarily focuses on novel antigen design based on the bioinformatics analysis of recent circulating isolates. Haemagglutinin-neuraminidase (HN) is one of the two main NDV antigens. Two HN fragments ("1"-341-368 aa and "2"-239-257 aa) were selected due to the presence of linear neutralising epitopes. An approach focusing on using a number of selected-fragment variants simultaneously was applied for the first time. The resulting antigen Castle1 encompasses the sequence diversity of most circulating isolates. Preliminary immunological evaluation showed that antibodies from Castle1-immunised animals possessed haemagglutination inhibition activity and interacted with NDV of genotypes I and VII. That makes Castle1 a promising antigen for the further development of a vaccine for preventing ongoing and incoming NDV outbreaks.
SN - 1422-0067
ER -